A microRNA molecular modeling extension for prediction of colorectal cancer treatment

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Li, Jian ^a,b   Mansmann, Ulrich R ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Colorectal cancer; Individualized medicine; MicroRNA regulation; Signaling pathway

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; MICRORNA; NILOTINIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ALGORITHM; ARTICLE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COMPLEX FORMATION; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG SENSITIVITY; FLUX COMPARATIVE ANALYSIS; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC PARAMETERS; HUMAN; LIGAND BINDING; MICROSATELLITE INSTABILITY; MICROSATELLITE STABILITY; MOLECULAR MODEL; PERSONALIZED MEDICINE; PREDICTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TREATMENT RESPONSE; VALIDATION STUDY; BIOSYNTHESIS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, MOLECULAR; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84935877565     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1437-0     Document Type: Article

References (50)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-73.
2. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012;5(1):19-27.
3. de Sousa EM, Wermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011;17(4):653-7.
4. Qian L, Wong B. Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009;30(12):1979-86.
5. Gulino A, Ferretti E, De Smaele E. Hedgehog signaling in colon cancer and stem cells. EMBO Mol Med. 2009;1(6-7):300-2.
6. Fang JY, Richardson BC. The MAPK signaling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322-7.
7. Wang S, Liu Z, Wang L, Zhang X. NF-kappeB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6(5):327-34.
8. Schetter AJ, Okayama H, Harris CC. The Role of microRNAs in Colorectal Cancer. Cancer J. 2012;18(3):244-52.
9. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and-145 in colon cancer. DNA Cell Biol. 2007;26(5):311-20.
10. Asangani IA, Rasheed SA, Nikolova DA, Leupoid JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128-36.
11. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385-92.
12. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund A. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010;5(1), e8836.
13. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375-81.
14. Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X, et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011;117(1):86-95.
15. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118-26.
16. Cheng H, Zhang L, Cogdell D, Zheng H, Schetter A, Nykler M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6(3), e17745.
17. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1766-74.
18. Hotchi M, Shimada M, Kurita N, Iwata T, Sato H, Morimoto S, et al. microRNA expression is able to predict response to chemoradiotherapy in rectal cancer. Mol. Clin Oncol. 2013;1(1):137-42.
19. Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet. 2010;200(2):154-60.
20. Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis. 2011;28(1):27-38.
21. Shibuya H, Linuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79(3-4):313-20.
22. Melo SA, Kalluri R. Molecular Pathways: MicroRNAs as Cancer Therapeutics. Clin Cancer Res. 2012;18:4234.
23. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11:R25.
24. NCI-60 RNA Expression Data Repository. http://discover.nci.nih.gov/datasets.jsp
25. NCI-60 CellMiner. http://discover.nci.nih.gov/cellminer
26. Li J, Mansmann U. Modeling of Non-Steroidal Anti-Inflammatory Drug Effect within Signaling Pathways and miRNA-Regulation Pathways. PLoS One. 2013;8(8), e72477.
27. Hanahan D, Weinberg R. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646-74.
28. Li J, Pandey V, Kessler T, Lehrach H, Wierling C. Modeling of miRNA and drug action in the EGFR signaling pathway. PLoS One. 2012;7(1), e30140.
29. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 2002;11(12):1845-57.
30. Walker EH, Pacold ME, Perisic O, Stephens L, Tawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. Mol Cell. 2000;6:909-19.
31. Holbeck S, Collins JM, Doroshow JH. Analysis of food and drug administration-approved anti-cancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther. 2010;9:1451-60.
32. Bland JM, Altman DG. Calculationg correlation coefficients with repeated observations: Part 1 - correlation within subjects. BMJ. 1995;310:446.
33. NSAID-miR model. ftp://138.245.80.137/NSAID_miR.xml
34. Wang J, Lu M, Qiu C, Cui Q. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res. 2010;38(Database issue):D119-22.
35. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-32.
36. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010;15(4):390-404.
37. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91(15):1295-303.
38. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342(2):69-77.
39. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-57.
40. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome instage II and III colorectal cancer patients. J Clin Oncol. 2006;24(15):2359-67.
41. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-74.
42. Jernvall P, Maekinen MJ, Karttunen TJ, Maekelae J, Vihko P. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer. 1999;35(2):197-201.
43. Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, et al. Microsatellite instability in sporadic colorectal carcinomas is not an indicator of prognosis. J Pathol. 1999;188(1):14-7.
44. Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L, et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer. 1999;81(2):190-3.
45. Gafa R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer. 2000;89(10):2025-37.
46. Cancer Genome Atlas. http://cancergenome.nih.gov
47. Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011;141(1):50-61.
48. Thompson C, Leong S, Messersmith M. Promising targets and drugs in development for colorectal cancer. Semin Oncol. 2011;38(4):588-97.
49. Tejpar S, Delorenzi R, Fiocca R, Yan P, Klingbiel D, Dietrich D, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol. 2009;27:15s.
50. Ellwanger DC, Leonhardt JF, Mewes HW. Large-scale modeling of condition-specific gene regulatory networks by information integration and inference. Nucleic Acids Res. 2014;42:21.